Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling - Wikidata - wikimedia - TriplyDB

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

http://www.wikidata.org/entity/Q35036800

about

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder The biology of castration-resistant prostate cancer Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.Prostate changes related to therapy: with special reference to hormone therapy.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.Current role of cabozantinib in metastatic castration-resistant prostate cancer.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Cabozantinib for the treatment of kidney cancer.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Cabozantinib in genitourinary malignancies.C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.Effective combinatorial immunotherapy for castration-resistant prostate cancer Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone.BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.Bone-Targeted Therapies in Cancer-Induced Bone Disease.Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer.

P2860

Q27853074-B4CAAF2C-CEED-4664-99F7-E52DD19B8255 Q28082793-C61CBACB-984F-463E-BD7F-CD19B5BAC087 Q34330748-AD25E94E-39B5-462C-9481-6381FA646F90 Q34657338-F9BDEFE6-20C1-47A2-B4CB-682E1BDC9F47 Q34774912-DD71777C-F2A1-458A-AD8E-9E14E532F76F Q35039889-A2B965FD-23A6-4856-B34C-B0B513980F40 Q35252908-71AD791D-188D-41AF-AABB-F5AC4B75EAA7 Q35344149-B26D4535-A0A9-4731-AD43-FBB4AE2067B0 Q35985270-628E1E37-B0E3-493F-9D1C-86821F0023DD Q36621024-4976D2A0-BFFC-4C03-8FBC-627F7D33260D Q38317384-EED0F41B-6074-425B-9B69-E9BBC7DF6C01 Q38430335-46DEFEF6-F9A3-4CE0-A0CD-7A521E1D893A Q38668871-E9C1FC70-0F13-4CA0-9540-BD77B2B0E177 Q38723404-22924E3F-7894-4B31-B9AE-34B6A35CD2CA Q38746778-C405D9BE-B60D-441E-BF5D-C70513F3A243 Q38795560-DCFE4B5B-16C7-47D6-A5FE-3CE498CED20A Q38964120-54A676A7-3418-4184-A391-43B9E0E40777 Q39085996-1503A427-5F82-45C5-82B0-8D8F22497012 Q41716558-0332AB34-6998-4E58-9167-A70C018B42BE Q42135817-5A867BE1-1F53-4322-92C3-17E5DAF06984 Q42315779-CFD5659A-90AE-43EF-98AB-5E83A89E79CE Q44676922-9E727A6F-8A47-4058-9E87-CE16860356EB Q47129742-89CFCB09-6650-4807-8C3C-E031B268CD6C Q48110513-F72BD881-D945-4AC1-A542-2C132539A038 Q52900925-807849D1-FCD7-4DCF-B6ED-D629B9AF0EE1

P2860

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

http://www.wikidata.org/entity/Q35036800

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@ast

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@en

type

label

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@ast

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@en

prefLabel

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@ast

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@en

P1433

Q35036800-2B1FD25A-EF0C-4BA8-A52E-75284E05D8D9

P1476

Q35036800-18556078-383B-4D69-882B-7EF0285F033D

P2093

Q35036800-462A5184-5A2A-4559-89A4-9E17799AD04F

Q35036800-4FE22754-DD55-4D98-A20E-11FDBCA54B0B

Q35036800-6A9A5360-EA7C-4689-8248-CD3ECCC0CF47

Q35036800-8F807C91-01AD-4CA7-862D-626D68D68F35

Q35036800-9F37551C-C736-4061-B8C1-2194B14F1B73

Q35036800-CA030D0D-925F-4E3B-87BC-7C41DB4C868D

Q35036800-DF19E548-AEF8-4C34-BFDA-997F46B58CE7

Q35036800-E4D709E8-12DE-409B-BC11-9655FD4AE176

Q35036800-F36AC7AC-FDD6-441F-8731-48D0FDE8D701

Q35036800-FA12ABAF-3B87-46FB-A479-738E48AB9275

P2860

Q35036800-01C5AE63-59E7-45A4-848F-6A3F649B5A5A

Q35036800-086F9134-220D-47C4-A7F6-4F94EE6A7D94

Q35036800-088F9E95-07BD-4C46-BDE3-0353569474C0

Q35036800-09A4F837-5EC6-4174-B15A-F2F1C30BCE5E

Q35036800-0AD107E5-3BE2-44BA-B212-7DAFFFB283F4

Q35036800-2AA8D982-81DC-424A-A3EC-E19999B85646

Q35036800-3345555C-5A6E-41FA-9ACD-D8168A8BE4E5

Q35036800-4D4B0729-8CA3-406A-8492-432C6B243D5B

Q35036800-57B31AAB-FF61-4D52-8738-918E3D6A96D4

Q35036800-57D4DB2F-24B7-45FD-B3DF-E9873B932A0A

P304

Q35036800-FAC7499D-54BE-478B-9FB4-4506A8307608

P31

Q35036800-7E29BC13-767B-4394-AB72-EA19572C85FB

P356

Q35036800-90B44603-4E90-4167-A6B2-CB9AC68DFA2B

P407

Q35036800-48FCEEB3-7022-410D-BCB6-95A5808B3C20

P433

Q35036800-D8F5B45A-F5FF-40CB-B7F8-0408D2443B12

P478

Q35036800-CA264F38-4703-406B-8481-6215B6EF69D7

P577

Q35036800-26928378-26C3-4468-9FDA-D2328CA0052E

P5875

Q35036800-DD5752DB-672C-4C26-876F-D4E62F033692

P698

Q35036800-F75FBB38-8BC8-423A-A72B-E7CDE5C411B1

P932

Q35036800-AD068E1F-9DEF-4F75-9259-F7AE85ECBBC6

P356

JOURNAL.PONE.0078881

P1433

P1476

Cabozantinib inhibits growth o ...... er and affects bone remodeling

@en

P2093

Colm Morrissey

http://www.w3.org/2001/XMLSchema#string

Dana T Aftab

http://www.w3.org/2001/XMLSchema#string

Eva Corey

http://www.w3.org/2001/XMLSchema#string

Frauke Schimmoller

http://www.w3.org/2001/XMLSchema#string

Holly M Nguyen

http://www.w3.org/2001/XMLSchema#string

Lisha G Brown

http://www.w3.org/2001/XMLSchema#string

Nazanin Ruppender

http://www.w3.org/2001/XMLSchema#string

Robert L Vessella

http://www.w3.org/2001/XMLSchema#string

Roman Gulati

http://www.w3.org/2001/XMLSchema#string

Ted S Gross

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Prostate cancer and the met hepatocyte growth factor receptor

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

HE3235 inhibits growth of castration-resistant prostate cancer.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche.

Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Efficacy of c-Met inhibitor for advanced prostate cancer.

P304

e78881

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0078881

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258351405

http://www.w3.org/2001/XMLSchema#string

P698

24205338

http://www.w3.org/2001/XMLSchema#string

P932

3808282

http://www.w3.org/2001/XMLSchema#string